NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Exonate

Exonate

Private
CambridgeHealthcare & Life Scienceshttps://www.exonate.com/

Last Round

Series A

Jan 3, 2019

Total Funding Raised

$11.79M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Exonate is a biopharmaceutical company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

topical eye dropsSRPK1 inhibitorwet AMDdiabetic macular oedemaDMEsmall-molecule drugsmRNA splicing modulationVEGF modulationretinal disease therapynon-invasive treatmenteye injections alternativeclinical-stage biotechdiabetic retinopathypharma partnershipsdrug licensingwet age-related macular degenerationNPDREXN407

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Exonate Comparables

Compare Exonate with similar companies based on industry and business-model similarity.

Exonate comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
PanOpttica
88%
Retinset, S.L.
82%
Anida Pharma
82%

Exonate Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 3, 2019
GrantFeb 6, 2017
AngelNov 30, 2016
AngelOct 5, 2015
SeedApr 3, 2014

Key People

Founding team and executive leadership

Loïc Lhuillier

Chief Operating Officer

Executive Team

Exonate Investors

Notable investors and investment history

Exonate investors
InvestorRounds
ACF InvestorsAngel, Series A
IP GroupSeed
o2h venturesAngel, Series A
University of Bristol Enterprise FundAngel, Series A
UniseedAngel, Series A
Parkwalk AdvisorsAngel, Series A
Wren CapitalAngel, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 22, 2026

    Monthly visitors increased 58% MoM.

  • Feb 6, 2017

    Secured $6.1M from Wellcome Trust.

Exonate Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Exonate Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Exonate's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge
Employee Range16
Year Founded2013
Last FundingJan 3, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.